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Abstract
Leptospirosis is an important global human and veterinary health problem. Humans can be infected by exposure to chronically 
infected animals and their environment. An important focus of the current leptospiral research is the identification of outer mem­
brane proteins (OMPs). Due to their location, leptospiral OMPs are likely to be relevant in host-pathogen interactions, hence their 
potential ability to stimulate heterologous immunity. The existing whole-genome sequence of Leptospira interrogans serovar Copen­
hagen! offers a unique opportunity to search for cell surface proteins. Predicted genes encoding potential surface proteins were 
amplified from genomic DNA by PCR methodology and cloned into an Escherichia coli expression system. The partially purified 
recombinant proteins were probed by Western blotting with sera from human patients diagnosed with leptospirosis. Sixteen pro­
teins, out of a hundred tested, were recognized by antibodies present in human sera. Four of these proteins were conserved among 
eight serovars of L. interrogans and absent in the non-pathogenic Leptospira biflexa. These proteins might be useful for the diagnosis 
of the disease as well as potential vaccine candidates.
© 2005 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.
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1. Introduction
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Leptospirosis, an emerging infectious disease, is a 
worldwide zoonosis of human and veterinary concern. 
Caused by spirochaetes of the genus Leptospira, the dis­
ease presents greater incidence in tropical and subtropi­
cal regions [1,2]. The transmission of leptospirosis has 
been associated with exposure of individuals in close 
proximity to wild or farm animals [3]. Recently the 
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disease became prevalent in cities with sanitation prob­
lems and large population of urban rodent reservoirs, 
which contaminate the environment through their urine 
[4]. The incidence of leptospirosis remains underesti­
mated in part due to the broad spectrum of signs and 
symptoms that patients may present. Children primarily 
show fever, vomiting, headache, diarrhea, abdominal 
and generalized muscle pain, whereas adults have fever, 
headache, anorexia, muscle pain and constipation [4,5]. 
Five percent to 15% of the cases evolve more severely 
presenting hemorrhages with renal and hepatic failure, 
a condition known as Weil’s syndrome [4], with a mor­
tality rate of 5-40%. Leptospirosis has also a great eco­
nomic impact in the agricultural industry since the 
disease affects the livestock inducing abortions, still­
births, infertility, reduced milk production and death 
[3,4].
Currently available veterinarian vaccines are based 
on inactivated whole cell or membrane preparations 
of pathogenic leptospires. These types of vaccine con­
fer protective responses through induction of antibod­
ies against leptospiral lipopolysaccharide [6]. However, 
these vaccines fail to induce long-term protection 
against infection and do not provide cross-protective 
immunity against leptospiral serovars not included in 
the vaccine preparation. There is a large number of 
pathogenic serovars (>200) which imposes a major 
limitation to the production of a multi-serovar compo­
nent vaccine and to the development of immunization 
protocols based on whole cell or membrane prepara­
tions. In humans, a prototype vaccine has been tested 
in China but children under 14 years were not pro­
tected [7]. A vaccine licensed for human is still long 
awaited [4]-
The advent of whole-genome sequencing has made 
an impressive impact in the microbial field landscape. 
The complete genomic sequence of Neisseria meningit­
idis serogroup B offered a new strategy for the identi­
fication of vaccine candidates [8]. This landmark 
approach, now called reverse vaccinology, has been 
applied in the last few years revolutionizing the vac­
cine research area [9,10]. The design of vaccines is 
based on bioinformatic tools for the prediction of po­
tential antigens in silico, hence narrowing down the 
universe to be tested. In addition, this approach has 
the advantage of revealing proteins independently of 
their abundance and without the need of growing 
the microorganism in vitro [11].
In the present study, we describe 16 new leptospiral 
membrane-associated proteins selected from the genome 
of L. interrogans serovar Copenhagen! [12,13]. The 
rationale for the choice of these predicted coding se­
quences is that surface-associated molecules are poten­
tial targets for inducing immune responses in animals 
and may serve as vaccines against disease and/or for 
use in diagnostic tests.
2. Materials and methods
2.1. Bacteria
L. interrogans serovar Copenhageni sequenced strain 
(Fiocruz Ll-130) was provided by Dr. A.I. Ko 
(CPqGM/FIOCRUZ/MS). The strain was isolated as 
described [12]. L. interrogans serovars Canicola, Ict- 
erohaemorrhagiae, Copenhageni, Bratislava, Hardjo, 
Autumnalis, Pomona, Pyrogenes, Grippotyphosa and 
Leptospira biflexa serovar Patoc were maintained in 
one of our laboratories (S.A.V., Faculdade de Medicina 
Veterinària, Universidade de Sào Paulo, SP, Brazil).
2.2. In silico identification of surface proteins
Protein coding genes from the L. interrogans genome 
sequence were identified using GeneMark and Glimmer 
[14]. The PSORT program [15] (http://psort.nibb.ac.jp/) 
was then used to predict the localization of the coded 
proteins within the bacterium. Public and custom se­
quence-specific search algorithms were used for identifi­
cation of sequence motifs including signal peptides, 
lipoprotein cleavages sites and transmembrane domains 
(http://www.cbs.dtu.dk/services/TMHMM) [16] and 
(http://www.cbs.dtu.dk/services/SignalP) [17]. In addi­
tion, putative proteins, homologous to surface proteins 
previously characterized as virulence factors in other 
organisms, were searched for by blast analysis (http:// 
www.ncbi.nlm.nih.gov/BLAST/) [18]. In this work, the 
predicted coding sequences are referred to according 
to their genome nomenclature, LIC [12].
2.3. Cloning, expression and purification
Cloning techniques were performed according to 
Sambrook et al. [19]. For the expression of the selected 
predicted coding sequences the Gateway® (Invitrogen) 
cloning and expression system was used. Each selected 
DNA sequence was amplified by PCR from Leptospira 
genomic DNA using Pfx DNA polymerase (Invitrogen) 
and primers specially designed following the manufac­
turer recommendations. In this system, the PCR prod­
ucts are first cloned into pENTR TOPO vector 
(Invitrogen). The correct orientation is obtained by add­
ing four bases to the forward primer (CACC) which an­
neals to a complementary overhang in the cloning vector 
(GTGG). In Table 1, there is a list of primers for PCR 
amplification of 17 coding sequences which became of 
special interest in this report. When necessary, DNA 
bands were extracted from agarose gel using Concert 
purification system (Gibco BRL) following the manu­
facture’s protocol. The sequence of the cloned leptospira 
DNA insert was confirmed by sequencing and trans­
ferred by recombination reaction by LR Clonase (Invit­
rogen) to the Escherichia coli expression vector
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Table 1
Sequence of the primers employed for DNA amplification and molecular mass of native and expressed recombinant proteins
Gene id genome nomenclature Primers for PCR amplification Molecular mass (kDa)
Native Recombinant
LIC10054 F CACCACGTCTTGTGCGTCGGTAGAG 35.6 35.1
R CCAAGTATTCTATTTATACGTCCGAG
LIC 10091 F CCATGGGACTCGAGACGCCTCCTCCTAAAGATCC 40.6 39.0
R CTCCATGGTCATTTCAAAACTTCTACGGGGC
LIC10508 F ACCATGGGATCCGCTCTTTTGGTTGATCCAGAG 23.0 18.5
R GAATTCCTAACAACCAGGACCTTCACAT
LIC 11947 F CACCCCTTCGAGGTTGGAAATCG 20.1 22.8
R AATCGATGGATCACGTTACG
LIC10561 F CACCAAGAAGGATTCCAACGATGATG 33.1 32.0
R TCTCCTGCTTGACAGCCGAC
LIC10765 F CACCGAAAGTCCCGTAAGGTTCAAA 16.6 15.4
R TGCAGGAGTTCCCACATTTTA
LIC11271 F CACCAATCGACTTTTCACTGAGTTTCTT 30.9 29.2
R CGAAAGTATCAAGAAGAACCGTA
LIC 11574 F CACCATCATTCCTTCGGGAAGTGAC 21.2 20.6
R CCATTCTCTGTTGTTTGATCCC
LIC12518 F CACCCCGTGTTCTTTTGGTTTAGAT 15.8 15.9
R TTCCAACAAATCGAATCATCT
LIC13131 F CACCACGTCTCAAAGTTACGCTTCAG 23.0 21.9
R TTCTCACCATCCAGCTCGG
LIC10380 F CACCATGGGCGCTTTTAATCGG 20.9 21.9
R CGGAACTAGGGAACTTTTCAAC
LIC12099 F CACCACCAATGTGTTTGGTATAGCG 52.7 53.8
R CAGCGTTTTGTGATAAAATTAAC
LIC12228 F CACCAAACCTGGATATGGAATGGC 17.3 18.4
R TACAGAGGTAGAAGCGTTAGAAG
LIC13306 F CACCTTTGCACAATCCAAAGAGAAATG 20.1 21.2
R TCATTTCCGAACCGGATGAC
LIC10191 F CACCGAGCCTTCAACGCAAGAGCAA 18.7 20.6
R AACGTAAGACGTTGAGTTGCCACA
LIC13008 F CACCATGCGTGCTGTCAGTAGAGAAAC 15.3 15.2
R GTCG ACATTG GCAG AATTTACG
LIC11352 F CACCGGTGCTTTCGGTGGTCTG 29.6 30.2
R ATTACTTAGTCGCGTCAGAAGC
LIC: Leptospira interrogans Copenhageni.
pDEST17. The vector containing the correct DNA se­
quence was cloned into E. coli BL21(DE3) (Novagen) 
for protein expression as previously described [20]. The 
production of recombinant proteins was achieved by 
the addition of isopropyl P-D-thiogalactoside (IPTG) 
to the medium. The pDEST17 vector allows the expres­
sion of recombinant proteins with 6 x His-tag at the N- 
terminus. Most of the assays were performed in high 
throughput scale with 96 samples each round. The first 
screening to check the protein expression was done by 
SDS-PAGE with total protein extracts from each clone. 
Proteins from expressing clones were purified from the 
pellets of the cell extracts, by solubilization in 8 M urea, 
followed by metal affinity chromatography using QIAfil- 
ter 96 plates Ni-nitrilotriacetic acid resin superflow 
(Qiagen) as described by the manufacturer. In brief, 
contaminants were washed away with 10 vol. of binding 
buffer, 20 mM Tris, 500 mM NaCl, containing 5 or 20 
mM imidazole. Recombinant protein samples were 
eluted with 5 vol. of the same buffer but with 1 M imid­
azole. Eluted fractions were analyzed by SDS-PAGE, 
through 12-15% (wt/vol) acrylamide concentration 
according to the expected molecular mass of the 
proteins.
2.4. Mice antisera against recombinant proteins
Groups of 5, 6-8 weeks female BALB/c mice, (Insti­
tute Butantan, Sao Paulo, SP, Brazil) were immunized 
subcutaneously with approximately 15 pg of each re­
combinant protein with complete Freund’s adjuvant. 
After 21 days, mice were boosted with the same amount 
of protein in incomplete Freund’s adjuvant. Twenty­
eight days following the booster the animals were bled 
and immune titers were determined by antibody capture 
endpoint enzyme-linked immunosorbent assay (ELISA). 
The control group was inoculated with PBS and 
adjuvant.
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2.5. Recognition of recombinant proteins by sera from 
leptospirosis patients
Cell pellets of induced bacteria as well as purified pro­
teins were separated by 12-15% SDS-PAGE and electro 
transferred to nitrocellulose membrane for Western 
blotting assay. Membranes were blocked with PBS con­
taining 0.1% Tween 20 (PBS-T) and 5% nonfat dry milk; 
after which they were incubated with individual human 
serum (microscopic agglutination test - MAT - titre of 
25,000, Instituto Adolfo Lutz, Sao Paulo, SP, Brazil) 
from convalescent patients diagnosed with leptospirosis 
at 1:100 dilution. Goat anti-human IgG peroxidase-con- 
jugate was used as secondary antibody at 1:1000 dilution 
in PBS-T. Proteins reacting with the antisera were de­
tected by reaction with DAB and H2O2 or with ECL 
Kit ( Amersham).
2.6. Recognition of proteins from leptospiral extracts by 
sera from mice immunized with recombinant proteins
Bacterial cultures of several leptospiral serovars were 
centrifuged and the cell pellets were resuspended and 
washed three times by centrifugation with PBS contain­
ing 5 mM MgCl2. The cell pellets were then resuspended 
in PBS containing 10% SDS and a sample from each 
serovar sample was applied on a 10% SDS-PAGE. Pro­
teins were transferred to nitrocellulose membrane and 
probed with serum obtained from mice immunized with 
each of the recombinant proteins.
2.7. Nucleotide sequence Accession Numbers
The sequences of the two chromosomes of L interro­
gans serovar Copenhagen! strain Fiocruz LI-130 have 
been deposited in the GenBank database under Acces­
sion Nos. AE016823 and AE016824. The accession 
numbers for public data base for each protein sequence 
analyzed in this work are listed in Table 2. The proteins 
can also be accessed by the genome nomenclature for 
the gene locus, LIC number (Leptospira interrogans 
Copenhageni).
3. Results
3.1. Identification of vaccine candidates from the 
leptospiral genome: in silico analysis
Our rationale for the selection of the predicted coding 
sequences is that surface associated molecules are poten­
tial targets for inducing immune responses in the host 
[8-11]. These sequences could be identified in the gen­
ome database by one or more sequence motifs com­
monly found in known surface proteins from other 
bacteria. A primary screening was performed using the 
Psort program [http://psort.nibb.ac.jp/] to identify puta­
tive proteins with predicted cellular localization from 
the inner to the outer bacterial membrane. Genes encod­
ing proteins with known cytoplasmic functions were ex­
cluded. In addition, we searched for exportation signal 
peptides, transmembrane domains, lipoprotein signa­
tures and homologies to known surface proteins [12]. 
The in silico approach resulted in a large number of 
genes covering ~20% of the total number of predicted 
proteins in the genome. From these sequences we fo­
cused the selection mainly on hypothetical, unknown 
proteins, having either signal peptide sequences or lipo- 
box motifs [12].
Table 2
Name, feature and accession number of the proteins reactive to sera of leptospirosis patients
Locus id Protein name Feature Protein Accession No.
LIC10054 MPL36 Lipoprotein, probable AAS68691
LIC10091 LipL40 Lipoprotein, probable AAS68725
LIC10508 LipL23 Lipoprotein, probable AAS69129
LIC11947 LipL22 Lipoprotein, probable” AAS70529
LIC10561 OMPL31 Leptospira conserved hypothetical protein AAS69182
LIC10765 MPL17 Leptospira conserved hypothetical protein AAS69382
LIC11271 OMPL30 Leptospira conserved hypothetical protein AAS69877
LIC 11574 OMPL22 Leptospira conserved hypothetical protein AAS70170
LIC12518 OMPL16 Leptospira conserved hypothetical protein AAS71083
LIC13131 MPL21 Leptospira conserved hypothetical protein AAS71676
LIC10380 OMPL21 Conserved hypothetical protein AAS69003
LIC12099 LipL53 Conserved hypothetical protein” AAS70670
LIC12228 OMPL17 Conserved hypothetical protein AAS70800
LIC13306 OMPL20 Conserved hypothetical protein AAS71848
LIC10191 OMPAL21 Membrane protein, peptidoglycan associated (OmpA-like) AAS68819
LIC13008 OMPL15 Hypothetical protein AAS71558
LIC11352 LipL32 Lipoprotein LipL32 AAS69953
MP. Lip and OMP stand for membrane protein, lipoprotein and outer membrane protein, respectively; OMPA stands for OMPA-like domain; L. 
refers to Leptospira, while the numbers are related to the molecular mass of the protein.
Probable lipoproteins according to criteria described in Nascimento et al. [12] and Haake [22],
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3.2. Cloning and expression of vaccine candidates
Oligonucleotides for PCR amplifications (Table 1) 
were designed from the genome without the signal 
peptide sequences, which typically contain 18-28 
nucleotides, as described in experimental procedures. 
From 206 selected coding sequences (see Table 1, sup­
plementary data), more than 97% were amplified. The 
correct sequences were confirmed by DNA sequencing 
and 175 genes (84%) were successfully cloned into 
pENTR. The DNA inserts were transferred by recom­
bination from pENTR to pDEST17 expression vector. 
This E. colt vector expresses the recombinant proteins 
with six histidine residues at the N-terminus which al­
lows a rapid purification of the protein by metal che­
lating chromatography. We have expressed and 
purified 150 recombinant proteins with this system. 
A representative set of SDS-PAGE containing cell ex­
tracts from induced E. colt BL21(DE3) cultures 
expressing the recombinant proteins is shown in Fig. 
1. Based on the results obtained with the immune as­
says (see below), 16 proteins were found to be of spe­
cial interest and the data related to them are 
highlighted along this report. Some of these proteins 
are indicated in Fig. 1.
The majority of the recombinant proteins were 
found to be insoluble in the pellets of bacterial cell ly­
sates, as evaluated by SDS-PAGE (not shown). The 
inclusion bodies were isolated, urea-solubilized and 
purified by metal affinity. The purified proteins were 
grouped according to their molecular mass and ana­
lyzed by SDS-PAGE. A representative set of these gels 
is shown in Fig. 2, in which numbered lanes refer to 
proteins reactive to sera of leptospirosis patients (see 
below).
M 1 2 3M 4 M 5
31 to 38 KDa
MM 6 M
38 to 43 KDa 43 to 53 KDa
70-
50—
40—
30—
25-
Fig. 1. Protein expression analysis by SDS-PAGE. Representative gels showing the cell extracts of BL21(DE3) E. coli transformed with different 
expression vectors. Proteins are assembled according to their expected molecular mass. Lane numbers refer to sera-reactive proteins: (1) OMPL16. (2) 
OMPL15. (3) MPL17. (4) LipL22. (5) OMPL31 and (6) LipL53. M indicates the protein molecular mass marker.
3.3. Screening recombinant proteins for reactivity with 
leptospiral antisera
Purified proteins were screened for reactivity by immu­
noblotting with pooled sera from patients diagnosed with 
leptospirosis. The recombinant lipoprotein LipL32 was 
used as a positive control since it was shown to be immu­
nogenic and highly conserved among Leptospira patho­
genic serovars [20,21]. A total of 16 proteins out of a 
hundred tested were recognized by sera from leptospiro­
sis’s convalescent patients (Fig. 3). Table 2 summarizes 
features of these sera-reactive recombinant proteins.
3.4. Features of the proteins recognized by antibodies
The recombinant proteins listed in Table 2 were rec­
ognized by human sera from patients diagnosed with 
leptospirosis. They are all predicted to be membrane 
proteins with a signal peptide of 20-36 amino acids, as 
indicated by the software described in Bendtsen et al. 
[17]. Seven of these proteins (indicated by ** in Table 
2) are probably new leptospiral lipoproteins according 
to the criteria previously described [12,22]. The signal 
peptides regions are characterized by a higher propor­
tion of hydrophobic amino acids, a lipoprotein signal 
peptidase and a cysteine to be lipidated [22]. No specific 
function could be attributed to these putative lipopro­
teins. LIC10054 encodes a rare lipoprotein domain to 
which homologs were already found in other microor­
ganisms according to GeneBank database [http:// 
www.ncbi.nlm.nih.gov/BLAST/] [18]. Interestingly, the 
protein named OMPL15 (LIC13008) did not match 
any sequence in the available protein databases and 
should be considered for further studies on protein func­
tion. The protein encoded by LIC10191 has been
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Fig. 2. Purification of recombinant proteins. Representative SDS-PAGE containing samples of purified proteins obtained by high throughput metal 
affinity chromatography purification system. Proteins are assembled in the gels according to their expected molecular mass. Lane numbers refer to 
sera-reactive proteins: (1) OMPL15. (2) MPL17. (3) OMPL16. (4) OMPL30. (5) MPL21. (6) OMPL21. (7) LipL22. and (8) OMPL22. M indicates the 
protein molecular mass marker.
15 to 17 kDa
M
42 to 50 kDa
recently characterized from L. interrogans serovar Man- 
ilae, strain UP-MMC, as a novel lipoprotein with an 
OmpA domain [23]. Three proteins out of the 16 were 
found to be hypothetical proteins conserved among 
other microorganisms, while five were hypothetical pro­
teins conserved only among Leptospira species (Table 2), 
according to the currently available databases.
3.5. Conservation of antigenic proteins among leptospiral 
serovars
Protein expression in the most prevalent pathogenic 
serovars of L. interrogans is an important requirement 
for leptospiral vaccine candidates. In order to character-
ize the conservation of the selected proteins we em­
ployed protein extracts from several L. interrogans 
serovars: Canicola, Icterohaemorrhagiae, Copenhageni, 
Bratislava, Hardjo, Autumnalis, Pomona, Pyrogenes, 
Grippotyphosa and the nonpathogenic strain L. biflexa 
serovar Patoc. Cell extracts were prepared from cultures 
of the different serovars and Western blot analysis was 
performed with polyclonal sera from mice immunized 
with each recombinant protein. The serological cross­
reactivity showed a high degree of conservation among 
four out of 10 proteins tested (Fig. 4). Interestingly, 
none of these four proteins were present in the non­
pathogenic L. biflexa strain, suggesting that they may 
be relevant for pathogenesis. Most of the proteins reac-
1 2 3 4 5 6 7 8 M 1 9 10 11 12 13 14 15 M 1 16 17M
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Fig. 3. Recognition of recombinant proteins by leptospirosis human serum. Proteins blotted into nitrocellulose membranes were probed with serum 
(1:100 dilution) from individual covalescent patient diagnosed with leptospirosis (microscopic agglutination test - MAT - titre of 25.000. Institute 
Adolfo Lutz. Sao Paulo. SP. Brazil). Anti-human IgG-peroxidase conjugate was used as the secondary antibody and the bands were developed with 
DAB/H2O2. Lanes: 1. LipL32 (30.2); 2. LipL40 (39.0); 3. LipL23 (18.5); 4. OMPL20 (21.2); 5. OMPL15 (15.2); 6. OMPL31 (32.0); 7. OMPL16 (15.9); 
8. LipL53 (53.8); 9. MPL21(21.9); 10. MPL17 (15.4); 11. OMPL22 (20.6); 12. OMPL21 (21.9); 13. OMPL30 (29.2); 14. OMPL17 (18.4); 15. LipL22 
(22.8); 16. MPL36 (35.1) and 17. OMPAL21 (20.6). Numbers in parenthesis are the molecular mass of the recombinant proteins. M indicates the 
protein molecular mass marker.
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10 111234 567 89
OMPAL21 (LIC10191)
123456789 10 11
LipL23 (LIC10508)
OMPL31 (LIC10561)
MPL36 (LIC10054)
1 23456789
Fig. 4. Conservation of proteins among pathogenic leptospires. Whole cell lysates were prepared from representative strains of L. interrogans 
serovars. Proteins from the lysates were separated by electrophoresis, transferred into nitrocellulose membranes and probed with mice antisera raised 
against the recombinant proteins, as indicated by protein name and LIC number. Serovars in lanes are: 1. Canicola; 2. Icterohaemorrhagiae; 3. 
Copenhageni; 4. Bratislava; 5. Hardjo; 6. Autumnalis; 7. Pomona; 8. Pyrogenes; 9. Grippotyphosa; 10. L. biflexa sv Patoc; 11. respective purified 
recombinant protein (positive control).
10 11
LipL32 (LIC11352)
five with human leptospirosis serum shared roughly 
comparable expression levels among the different sero­
vars tested, but LIC10508 and LIC10561 were more 
variable.
4. Discussion
Considering that L. interrogans has an AT rich gen­
ome, with a 35% G + C content, [12], which imposes cer­
tain difficulties for primer design, it was above 
expectations to have amplified more than 97% of the 
206 coding sequences, as well as to have expressed and 
purified more than 80% of the cloned products. By 
screening with immune sera from leptospirosis patients 
16 proteins were identified as potential vaccine candi­
dates or to be used in diagnosis. The fact that these pro­
teins react with infected human sera not only shows 
their immune reactive properties, but also strongly sug­
gests that these proteins are expressed in the course of 
human infection. Interestingly, one of them (OMPL15) 
did not match at all any protein sequence in the public 
databases and deserves further studies to characterize 
its origin and function.
The central mechanism in pathogenesis of leptospiro­
sis, as in other spirochetal diseases such as Lyme disease 
and syphilis, is the ability of the pathogens to dissemi­
nate widely within the host during the early stage of 
infection [4]. Although surface-associated proteins that 
play a role in virulence have not been yet identified, it 
is assumed that they may mediate interactions that en­
able entry and dissemination through host tissues. Puta­
tive outer membrane proteins would be accessible to the 
immune response during host infection and therefore, 
constitute targets for immune protection through mech­
anisms such as antibody-dependent phagocytosis and 
killing mediated by complement. In this regard, a major 
limitation in the field of leptospirosis has been to iden­
tify membrane associated proteins through conventional 
biochemical and molecular methods. For instance, be­
fore the complete genome sequence of a leptospira was 
known, only 10 lipoproteins had been characterized 
through isolation of membrane fractions [24-29]. Using 
the genome approach, we have identified 174 novel 
putative lipoproteins [12]. In addition, the identified lep­
tospiral proteins may also have diagnostic applications. 
At present, rapid and efficient diagnostic tests are not 
available for use in human and veterinary leptospirosis 
[1,2,4]. A proportion of these membrane proteins will 
be antigens expressed during infection and should be 
recognized by the host immune system. Therefore, they 
may serve as the basis to develop antigen-capture detec­
tion strategies or recombinant protein-based serologic 
tests.
Our results corroborate previous studies showing the 
advantages of using whole genome approach [10,11] for 
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the identification of novel vaccine antigens at a reason­
able cost and time compared with traditional strategies.
We believe this work represents an important contri­
bution to the leptospiral field. The proteins described 
herein may certainly be exploited for the establishment 
of a much-needed kit for diagnosis of leptospirosis. Fur­
thermore, these proteins may provide an optimal basis 
for the development of a new and effective vaccine that 
would help reduce the burden of leptospirosis.
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